The Saudi Arabia osteoarthritis therapeutics market was valued at USD 80.03 Million in 2025 and is expected to grow at a CAGR of 3.80%, reaching USD 116.21 Million by 2035. Market growth is fueled by increasing prevalence of osteoarthritis and adoption of innovative treatment options.
Base Year
Historical Period
Forecast Period
The market size is expanding due to an aging population, rising obesity rates, and advancements in intra-articular therapies like extended-release corticosteroids and viscosupplementation, enhancing treatment efficacy.
The development of biologic therapies for cartilage repair, and integration of digital health solutions such as mobile apps and wearables to monitor joint health and treatment progress is amongst the major market trends.
The market comprises major pharmaceutical companies, medical device manufacturers, and biotech firms specializing in joint health and regenerative medicine, all contributing to the development and distribution of osteoarthritis treatments.
Compound Annual Growth Rate
3.8%
Value in USD Million
2026-2035
*this image is indicative*
Osteoarthritis therapeutics encompass a range of medical and supportive treatments aimed at alleviating joint pain, improving function, and slowing disease progression. These include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections, physical rehabilitation, lifestyle modifications, and in severe cases, joint replacement surgery. The market was valued at USD 80.03 Million in 2025. In Saudi Arabia, the market is experiencing steady growth due to an aging population, increasing obesity rates, rising healthcare investments, and greater awareness of musculoskeletal health.
Rising Aging Population and Prevalence of Osteoarthritis to Augment the Market Growth
The continuously growing elderly population in Saudi Arabia is a major factor significantly accelerating the expansion of the osteoarthritis (OA) therapeutics market. According to a comprehensive study published by Geetha Kandasamy et al. in February 2024, osteoarthritis prevalence increases notably with age, reaching 30.8% in individuals aged 46 to 55, and escalating to 60.6% among those aged 66 to 75. This explicit age-related rise in OA incidence is anticipated to considerably boost the demand for innovative and effective treatment solutions, thereby propelling consistent market growth over the forecast period.
Some of the notable trends in the market include strategic partnerships and the rising adoption of personalized medicine in Saudi Arabia.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Drug Class
Market Breakup by Dosage Form
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Knee Osteoarthritis Likely to Lead the Market
Among the common types of osteoarthritis such as hip osteoarthritis, spinal osteoarthritis, knee osteoarthritis, hand osteoarthritis, and others, knee osteoarthritis is expected to lead the market. This can be attributed to its high prevalence in the aging population and the increasing number of patients seeking medical intervention. The significant demand for effective therapeutic options and advancements in treatments for knee osteoarthritis will likely contribute to its dominance in the market.
The key features of the market report comprise clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Pfizer Inc., established in 1849 and headquartered in New York City, plays a vital role in the market with its anti-inflammatory product Feldene (Piroxicam 20 mg/mL solution for injection). Indicated for the symptomatic treatment of osteoarthritis, this intramuscular formulation is utilized particularly when oral or rectal administration is unsuitable. FELDENE's availability in the AfME region, including Saudi Arabia, highlights Pfizer’s ongoing regional engagement in delivering advanced rheumatologic care.
Bioventus Inc., founded in 2012 and headquartered in Durham, North Carolina, is a global leader in orthobiologics, offering clinically proven therapies that promote healing and mobility. In the Saudi Arabian osteoarthritis therapeutics market, Bioventus expanded its footprint with the introduction of Durolane, a single-injection hyaluronic acid product used for osteoarthritis pain relief. The company also launched Exogen, a bone healing ultrasound system, through a partnership with ZIMMO, reinforcing its commitment to musculoskeletal health in the region.
Founded in 1994 and headquartered in Riyadh, Saudi Arabia, Tabuk Pharmaceutical Manufacturing Company is a key player in the market. In 2023, Tabuk entered a licensing agreement with U.S.-based Levolta Pharmaceuticals to commercialize VOLT01, a novel investigational osteoarthritis drug, across the Middle East and Africa. VOLT01, showing promising Phase II/III results, represents a potential first-in-class disease-modifying therapy, aligning with Saudi Arabia’s Vision 2030 healthcare goals. Tabuk, a subsidiary of Astra Industrial Group, holds exclusive rights to market, register, and distribute VOLT01 in the region, reinforcing its leadership in providing advanced treatments for the region’s over five million osteoarthritis patients.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drug Class |
|
| Breakup by Dosage Form |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share